{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:17:02Z","timestamp":1787883422777,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study assessed the prognostic value and inter-\/intra-observer reliability of three amyloid PET interpretation methods\u2014conventional visual reading, assisted visual interpretation and standardized uptake value ratio (SUVR)-based quantification\u2014for predicting conversion to Alzheimer\u2019s disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective longitudinal study included 145 patients with amnestic mild cognitive impairment who underwent amyloid PET and were followed for up to 8 years at a single memory clinic. Two certified nuclear medicine physicians performed structured visual reads and assisted visual interpretations. Semiquantitative SUVR thresholds validated in prior studies were applied as a third method. Inter- and intra-observer agreement was assessed using Cohen\u2019s kappa (\u03ba). Cox regression models estimated the association of conversion to AD in PET-positive versus PET-negative patients for each method, adjusting for age, sex and education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Inter-observer agreement was excellent for structured visual reading (\u03ba\u2009=\u20090.877) and assisted visual interpretation (\u03ba\u2009=\u20090.904). Intra-observer reliability was also high (\u03ba\u2009=\u20090.891 for Reader 1; \u03ba\u2009=\u20090.859 for Reader 2). Consensus agreement for the assisted method reached \u03ba\u2009=\u20090.936. Amyloid PET positivity was strongly associated with progression to AD across all methods. Hazard ratios were highest for assisted visual interpretation (HR\u2009=\u20093.23, 95% CI 1.94\u20135.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), followed by SUVR quantification (HR\u2009=\u20092.19, 95% CI 1.55\u20133.10,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and structured visual reading (HR\u2009=\u20091.83, 95% CI 1.10\u20133.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Amyloid PET positivity consistently predicted conversion to AD regardless of interpretation method. Assisted visual and semiquantitative approaches showed numerically higher prognostic discrimination, while expert structured visual reading remained clinically reliable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08159-9","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:25:53Z","timestamp":1787880353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of Amyloid PET in Real-World Amnestic MCI: Influence of reader experience and interpretation method"],"prefix":"10.1007","author":[{"given":"Beatriz","family":"Echeveste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Fernando","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C. E.","family":"Hirschm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Riverol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"3","key":"8159_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138. https:\/\/doi.org\/10.1001\/archneur.56.3.303.","journal-title":"Arch Neurol"},{"issue":"1","key":"8159_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u20134. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"8159_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ. Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. JAMA Neurol. 2015;72(10):1183\u201390. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1633.","journal-title":"JAMA Neurol"},{"issue":"1","key":"8159_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"8159_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","volume":"82","author":"E Zeltzer","year":"2025","unstructured":"Zeltzer E, et al. Concordance between amyloid-PET quantification and real-world visual reads. JAMA Neurol. 2025;82(9):952\u201362. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2218.","journal-title":"JAMA Neurol"},{"issue":"3","key":"8159_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275\u201383. https:\/\/doi.org\/10.1001\/jama.2010.2008.","journal-title":"JAMA"},{"issue":"1","key":"8159_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/wjnm.WJNM_5_17","volume":"17","author":"K Kne\u0161aurek","year":"2018","unstructured":"Kne\u0161aurek K, Warnock G, Kostakoglu L, Burger C. Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging. World J Nucl Med. 2018;17(1):21\u20136. https:\/\/doi.org\/10.4103\/wjnm.WJNM_5_17.","journal-title":"World J Nucl Med"},{"issue":"12","key":"8159_CR8","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1007\/s00259-022-05846-1","volume":"49","author":"E Peira","year":"2022","unstructured":"Peira E, et al. A comparison of advanced semi-quantitative amyloid PET analysis methods. Eur J Nucl Med Mol Imaging. 2022;49(12):4097\u2013108. https:\/\/doi.org\/10.1007\/s00259-022-05846-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8159_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/J.JALZ.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/J.JALZ.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"8159_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"8159_CR11","unstructured":"Manual O, Neuro MI, Analysis C. MI Neuro Cortical Analysis."},{"key":"8159_CR12","unstructured":"Agency EM. Amyvid (florbetapir 18F) solution for injection. Summary of Product Characteristics. 2013; pp. 1\u201332."},{"key":"8159_CR13","unstructured":"Agency EM. Life Molecular Imaging. Neuraceq (florbetaben 18F) solution for injection. Summary of Product Characteristics. 2014; pp. 1\u201334."},{"key":"8159_CR14","unstructured":"European Medicines Agency. Vizamyl (flutemetamol 18F) solution for injection. Summary of Product Characteristics. 2021; pp. 1\u201338."},{"issue":"11","key":"8159_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0478-x","volume":"19","author":"B Tousi","year":"2017","unstructured":"Tousi B. Diagnosis and management of cognitive and behavioral changes in dementia with Lewy bodies. Curr Treat Options Neurol. 2017;19(11):42. https:\/\/doi.org\/10.1007\/s11940-017-0478-x.","journal-title":"Curr Treat Options Neurol"},{"issue":"10","key":"8159_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.neurol.2013.08.002","volume":"169","author":"F Pasquier","year":"2013","unstructured":"Pasquier F. New behavioural variant FTD criteria and clinical practice. Rev Neurol (Paris). 2013;169(10):799\u2013805. https:\/\/doi.org\/10.1016\/j.neurol.2013.08.002.","journal-title":"Rev. Neurol. (Paris)."},{"issue":"11","key":"8159_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"issue":"2","key":"8159_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/wnl.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n GC, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250\u201360. https:\/\/doi.org\/10.1212\/wnl.43.2.250.","journal-title":"Neurology"},{"issue":"12","key":"8159_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"1837","unstructured":"Emre M, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 1837;22(12):1689\u2013707. https:\/\/doi.org\/10.1002\/mds.21507.","journal-title":"Mov Disord"},{"key":"8159_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000478007","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, et al. Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dement Geriatr Cogn Disord. 2017;44:3\u20134. https:\/\/doi.org\/10.1159\/000478007.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"8159_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12149-024-01977-7","volume":"39","author":"A Takenaka","year":"2025","unstructured":"Takenaka A, et al. Interrater agreement and variability in visual reading of [18F] flutemetamol PET images. Ann Nucl Med. 2025;39(1):68\u201376. https:\/\/doi.org\/10.1007\/s12149-024-01977-7.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"8159_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"67","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging\u2013FDA approval of florbetapir F18 injection. N Engl J Med. 2012;67(10):885\u20137. https:\/\/doi.org\/10.1056\/NEJMp1208061.","journal-title":"N Engl J Med"},{"issue":"1","key":"8159_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl imaging. 2015;3(1):13\u201326. https:\/\/doi.org\/10.1007\/s40336-015-0102-6.","journal-title":"Clin Transl imaging"},{"issue":"11","key":"8159_CR24","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404\u201311. https:\/\/doi.org\/10.1001\/archneurol.2011.150.","journal-title":"Arch Neurol"},{"issue":"5","key":"8159_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-016-3591-2","volume":"44","author":"T Yamane","year":"2017","unstructured":"Yamane T, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of (11)C-PiB PET amyloid images of the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44(5):850\u20137. https:\/\/doi.org\/10.1007\/s00259-016-3591-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"8159_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3174\/ajnr.A4281","volume":"36","author":"AP Nayate","year":"2015","unstructured":"Nayate AP, et al. Use of standardized uptake value ratios decreases interreader variability of [18F] florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol. 2015;36(7):1237\u201344. https:\/\/doi.org\/10.3174\/ajnr.A4281.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"8159_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44(5):825\u201337. https:\/\/doi.org\/10.1007\/s00259-016-3601-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8159_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.12779\/dnd.2023.22.2.61","volume":"22","author":"C Simfukwe","year":"2023","unstructured":"Simfukwe C, Lee R, Youn YC. Classification of A\u03b2 state from brain amyloid PET images using machine learning algorithm. Dement Neurocogn Disord. 2023;22(2):61\u20138. https:\/\/doi.org\/10.12779\/dnd.2023.22.2.61.","journal-title":"Dement Neurocogn Disord"},{"key":"8159_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neurobiolaging.2017.06.027","volume":"59","author":"S Mathotaarachchi","year":"2017","unstructured":"Mathotaarachchi S, et al. Identifying incipient dementia individuals using machine learning and amyloid imaging. Neurobiol Aging. 2017;59:80\u201390. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.06.027.","journal-title":"Neurobiol Aging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08159-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:25:54Z","timestamp":1787880354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08159-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":29,"alternative-id":["8159"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08159-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was evaluated by the Ethics Research Committee of the University of Navarra and there were no ethical inconvenien for publication.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study at the time of the PET scan.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. It is not a clinical trial.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: Only Javier Arbizu received research grants from Life Molecular Imaging and Siemens through Clinica Universidad de Navarra, and lecture fees from Novartis\/Advanced Accelerator Applications, Eli Lilly, GE Healthcare, Life Molecular Imaging, Siemens and Zambon.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}